HMH Among First in Nation to Provide Latest Breast Biopsy Technology

HMH new Brevera system

Hardin Memorial Health’s (HMH) new Brevera Breast Biopsy System provides Central Kentuckians with the most advanced diagnostic technology available for patients with breast health concerns. HMH is the fourth healthcare system in the nation to offer this state-of-the-art technology and the first in the region.

The Brevera system allows radiologists to view the breast tissue sample in real time as the biopsy is taking place. Previously, physicians had to collect a series of samples, remove them from the device and X-ray them to make sure that the samples are adequate for diagnosis.

HMH Chief of Radiology, Stewart Couch, M.D., said if the samples were inadequate, they would have to take additional samples.

“Now we can see the sample immediately during the biopsy and know that we have what we need to properly diagnose patients,” said Couch. “The more efficient we can be, the better and more comfortable it is for patients.”

Couch added that the Brevera system is the world’s first biopsy system that allows for tissue acquisition, real-time imaging and post-biopsy analysis in one integrated system.

He said the streamlined process means the procedure is completed more quickly and with less tissue damage, resulting in a more positive biopsy experience for the patient.

“Patients are anxious when they have a breast biopsy,” said Couch. “Anything we can do to ease discomfort and finish more quickly is a win, and the Brevera system helps us do that.”

The HMH Board of Trustees approved more than $2.5 million in 2017 funding to purchase 3D mammography equipment and the Brevera system.

“Adding both 3D Mammography for screening and the Brevera system for biopsies enhance the strength of HMH’s Multidisciplinary Breast Care Program. The new technology, team of physicians and providers and nurse navigator mean patients with breast concerns can get all the specialized care they need here at home,” said Dennis Johnson, HMH President and CEO.